Vascular disease remains the leading cause of death and disability, the etiology of which often involves atherosclerosis. The current treatment of atherosclerosis by pharmacotherapy has limited therapeutic efficacy. Here we report a biomimetic drug delivery system derived from macrophage membrane coated ROS-...
The American Heart Association provides atherosclerosis treatment guidelines to health care providers and their patients.5 These guidelines are intended to prevent fatalities from atherosclerosis, nonfatal heart attacks, and damage to heart function, which could lead to heart failure. As noted earlier,...
Japan Atherosclerosis Society (JAS) published Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases 2002. According to the glob... H Mabuchi - 《Atherosclerosis Supplements》 被引量: 11发表: 2003年 Japanese Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiov...
Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis. 2007;195(2):339–47. https://doi.org/10.1016/j.atherosclerosis.2006.09.030. Article CAS PubMed Google Scholar Avis HJ, Vissres EA, Stein FA, ...
However, with progressive updates to treatment guidelines, advocating lower LDL-C goals, a greater proportion of patients will require use of combination therapy to reach these targets. This will require treatment of dyslipidemia to become similar to that of hypertension and type 2 diabetes, in ...
select article Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023 Review articleOpen access Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023 ...
In a 2006 MESA study that used the Third Report of the Adult Treatment Panel of the National Cholesterol Education Program to evaluate dyslipidemia management, men were more likely than women to be candidates of drug therapy but were less likely to be treated and have lipid level under control...
The 2019 ESC guidelines recommend that the COMPASS regimen should be considered for the treatment of patients with chronic coronary syndromes at high risk of ischaemic events and without high risk of bleeding.1 The COMPASS trial explained.
3A and H). Treatment with either NAC or rADAMTS13 attenuated the increase in plaque size, Mac2 staining, and MMP9 after MI. Compared to sham controls, mice undergoing MI without VWF-targeted therapy had less collagen as a proportion of total plaque size only (Fig. 3I and J). Anti-FXI...
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the ad... 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease ...